Homeopathic drugs Natrum sulphuricum and Carcinosin prevent azo dye-induced hepatocarcinogenesis in mice.
The study was undertaken to examine whether Carcinosin-200 (Car-200) could provide additional ameliorative effect, if used intermittently with Natrum sulphuricum-30 (Nat Sulph-30) against hepatocarcinogenesis induced by chronic feeding of p-dimethylaminoazobenzene (p-DAB) and phenobarbital (PB) in mice (Mus mnusculus). Mice were randomly divided into seven sub-groups: (i) normal untreated; (ii) normal + succussed alcohol; (iii) p-DAB (0.06%) + PB (0.05%); (iv) p-DAB + PB + succussed alcohol, (v) p-DAB + PB + Nat Sulph-30, (vi) p-DAB + PB + Car-200, and (vii) p-DAB + PB + Nat Sulph-30 + Car-200. They were sacrificed at 30, 60, 90 and 120 days for assessment of genotoxicity through cytogenetical end-points like chromosome aberrations, micronuclei, mitotic index and sperm head anomaly and cytotoxicity through assay of widely accepted biomarkers and pathophysiological parameters. Additionally, electron microscopic studies and gelatin zymography for matrix metalloproteinases (MMPs) were conducted in liver at 90 and 120 days. Results showed that administration of Nat Sulph-30 alone and in combination with Car-200 reduced the liver tumors with positive ultrastructural changes and in MMPs expression, genotoxic parameters, lipid peroxidation, gamma-glutamyl transferase, lactate dehydrogenase, blood glucose, bilirubin, creatinine, urea and increased GSH, glucose-6-phosphate dehydrogenasc, superoxide dismutase, catalase, glutathione reductase activities and hemoglobin, cholesterol, and albumin levels. Thus, intermittent use of Car-200 along with Nat Sulph-30 yielded additional benefit against genotoxicity, cytotoxicity, hepatotoxicity and oxidative stress induced by the carcinogens during hepatocarcinogenesis.
Cytogenetics and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani 741 235, India.
Nandini
N
Bhattacharjee
Pathikrit
P
Banerjee
Rahman Khuda-Bukhsh Anisur
RK
Anisur
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001391:Azo Compounds / Q000633:toxicity*; D015415:Biomarkers / Q000378:metabolism; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000188:drug therapy*; D004396:Coloring Agents / Q000633:toxicity*; D005260:Female; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D008419:Materia Medica / Q000627:therapeutic use*; D051379:Mice; D008854:Microscopy, Electron; D009153:Mutagens; D013431:Sulfates / Q000627:therapeutic use*; D013997:Time Factors
D016588:Anticarcinogenic Agents; D001391:Azo Compounds; D015415:Biomarkers; D002273:Carcinogens; D004396:Coloring Agents; D008419:Materia Medica; D009153:Mutagens; D013431:Sulfates; C012036:sodium sulfate